Baylor Researchers Unveil CS18, a Compound That Reverses Tumor Resistance to Standard Therapies
Baylor College of Medicine scientists have developed an experimental drug called CS18 that targets a central biological regulator to overcome cancer treatment resistance. By inhibiting the TopBP1 protein, CS18 weakens multiple survival pathways in tumor cells, restoring their sensitivity to existing therapies like osimertinib and PARP inhibitors. Early tests in animal models showed reduced tumor growth with minimal toxicity, suggesting potential for future combination treatments.